• Ahmed Kotb Abdrabou, Fahad Al Sharif, FakihRiad ElREFrom the Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, ZahraniHazaa AlHAFrom the Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, and HanbaliAmrAFrom the Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia..
• From the Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
• Ann Saudi Med. 2021 Jul 1; 41 (4): 198-205.

BackgroundIn 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT.ObjectivesDetermine the demographic characteristics of MM patients and the outcomes of ASCT.DesignRetrospective.SettingTumor registry database of major tertiary cancer care center in Riyadh.Patients And MethodsWe identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015.Main Outcome MeasuresThe demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS).Sample Size169 patients with newly diagnosed MM.ResultsThe median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (<1%) died in the first 100 days after transplantation.ConclusionsOur transplant eligible MM patients tend to be younger with a higher OS and a low ASCT-related mortality (<1%) than is reported internationally.LimitationsUsual limitations of a retrospective analysis using registry-level data; no data on quality of life.Conflicts Of InterestNone.

20 keywords...

hide…